STOCKHOLDERS’ EQUITY | NOTE 15 – STOCKHOLDERS’ EQUITY PREFERRED STOCK Series A As of December 31, 2021 and 2020, there were 2,000,000 Series A preferred shares authorized and zero Series A preferred shares outstanding. The board of directors had previously set the voting rights for the preferred stock at 1 share of preferred to 13 common shares . Series B As of December 31, 2021 and 2020, there was one ( 1 ) preferred share authorized and zero preferred shares outstanding. Series C As of December 31, 2021 and 2020, there were 3,000,000 Series C Preferred Shares (“Series C”) authorized with 544,500 and 2,145,030 issued and outstanding, respectively. The Series C shares have preferential rights above common shares and the Series B Preferred Shares and is entitled to receive a quarterly dividend at a rate of $ 0.06 per share per annum and have a liquidation preference of $ 1 per share. Series C shares outstanding are convertible into common stock at the rate of 20 preferred shares to one share of common stock. As of December 31, 2021 and 2020, the accrued dividends on the Series C Preferred Stock was $ 126 thousand and $ 253 thousand, respectively. In 2021, certain holders of Series C Shares elected to convert $ 1.6 million or 1,600,530 Series C shares and $ 194 thousand in accrued dividends in exchange for 105,551 OMNIQ common stock shares. The Series C Preferred Stock has a liquidation value and conversion price of $1.00 per share ($20.00 per 20 shares of preferred stock which convert to one share of common stock) and automatically converts into Common Stock at $1.00 per share ($20.00 per 20 shares of preferred stock which convert to one share of common stock) in the event that the Company’s common stock has a closing price of $30 per share for 20 consecutive trading days . COMMON STOCK In October 2021, OMNIQ’ Board of Directors adopted an Equity Incentive Plan (the “Plan”), as an incentive to retain in the employ of and attract new employees, directors, officers, consultants, advisors and employees to the Company. Pursuant to the Plan, 1,118,856 shares of the Company’s common stock, par value $ 0.001 (the “Shares”), were set aside and reserved for issuance. The Plan approved by our stockholders at the December 2021, shareholders’ meeting. No shares were issued under the Plan in 2021. In August 2020, OMNIQ’ Board of Directors adopted an Equity Incentive Plan (the “Plan”), as an incentive to retain in the employ of and attract new employees, directors, officers, consultants, advisors and employees to the Company. Pursuant to the Plan, one million ( 1,000,000 ) shares of the Company’s common stock, par value $ 0.001 (the “Shares”), were set aside and reserved for issuance. The Plan approved by our stockholders at the September 2020, shareholders’ meeting. For the year ending December 31, 2020, we issued 336,146 shares ($ 1.6 million) to consultants and advisors for services rendered. No shares were issued under the Plan in 2021. In December 2015, our Board of Directors approved the OMNIQ. Employee Stock Purchase Plan (the “ESPP”). For the years ending December 31, 2021 and 2020, employees purchased 2,186 ($ 16 thousand) shares and 302 ($ 1 thousand) shares of commons stock. On February 15, 2021 the Company issued 25,000 shares to Orion 4, LLC as part of a consulting agreement. The shares were valued at $ 188 thousand. On May 4, 2021, the Company issued 95,424 shares as part of a series of conversion agreements with a former noteholder and preferred shareholder. The shares were valued at $ 859 thousand including conversion penalties. On July 8, 2021, the Company issued 220,103 shares in connection with the acquisition of Dangot Computers. The shares were valued at approximately $ 2 million. See note 4. On July 8, 2021, the Company entered into a form of Securities Purchase Agreement (the “Securities Purchase Agreement”) with accredited investors. Pursuant to the Securities Purchase Agreement, on July 8, 2021 (the Closing Date”), the Company sold an aggregate gross proceeds of $ 15 million of units (the “Units”) before deducting placement agent fees, consultant and legal fees and other offering expenses (the “Offering”). The per Unit purchase price was $ 7.00 . Each Unit is comprised of one share of the Company’s common stock, $ 0.001 par value per share. As a result of the Offering, the Company issued 2,142,857 shares of common Stock (the “Shares”) and warrants (the “Warrants”) to purchase 171,429 shares of Common Stock (the “Warrant Shares”) at an exercise price equal to $ 7.70 per Warrant Share, which Warrants are exercisable for a period of five years from the issuance date. On October 13, 2021, the Company issued 10,127 shares as part of a series of conversion agreements with a former noteholder and preferred shareholder. The shares were valued at less than $ 100 thousand including conversion penalties. For the years ending December 31, 2021 and 2020, 342,667 and 216,750 , respectively, in stock options and stock warrants were exercised in exchange for 279,096 and 90,691 shares of OMNIQ common stock. In April 2020 and in conjunction with the Eyepax acquisition, we issued the former owner 80,000 share of OMNIQ common stock. In September 2020 and pursuant to the 2020 Equity Incentive Plan, we granted options to purchase an aggregate of 745,000 shares of our common stock to certain of our employees, officers and directors. Included in the total shares granted are options to purchase 230,000 shares of its common stock to Mr. Shai Lustgarten, our Chief Executive Officer, options to purchase 40,000 shares of its common stock to Mr. Neev Nissenson, our Chief Financial Officer, options to purchase 150,000 shares of its common stock to Mr. Carlos J. Nissensohn, a consultant and principal stockholder, and options to purchase 10,000 shares of its common stock to our Directors Andy MacMillan and Yaron Shalem, respectively. The remaining 305,000 granted options are for other employees and consultants. The exercise price of all of the options granted was $ 4.40 per share, which was the closing price of the Company’s common stock on September 29, 2020, the day prior to the grant, except for the options granted to Shai Lustgarten and Carlos J. Nissensohn, which have an exercise price of $ 4.84 per share. The options granted to Shai Lustgarten and Carlos J. Nissensohn have a term of five ( 5 ) years and the balance of the options have a term of ten ( 10 ) years. Warrants and Stock Options In connection with the July 2021 Securities Purchase Agreement previously described, we issued warrants to purchase 171,429 shares of our common stock at an exercise price equal to $ 7.70 per Warrant Share, which warrants are exercisable for a period of five years from the issuance date. The warrants were valued at $ 1.3 million. Options and warrants are valued at the grant date using the Black-Scholes valuation methodology. The Company determines the assumptions used in the valuation of warrants and option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at those grant dates. As such, the Company may use different assumptions for options and warrants granted throughout the year. The valuation assumptions used to determine the fair value of each warrants awarded in 2021: expected stock price volatility 151.0 % expected term in years 5 ; and risk-free interest rate 0.41 %. The valuation assumptions used to determine the fair value of each option/warrants awarded in 2020: expected stock price volatility 156.0 % - 157.0 %; expected term in years 4.0 - 5.5 ; and risk-free interest rate 1.40 % - 2.31 %. No additional options were issued in 2021. For warrants exercised during the year ended December 31, 2021, the difference between the fair value of the Common Stock issued and the respective exercise price was $ 683 8 6 The following table summarizes information about warrants granted during the years ended December 31: SCHEDULE OF WARRANTS ACTIVITY 2021 2020 Number of Weighted Number of Weighted Balance, beginning of year 1,366,667 $ 7.19 1,166,667 $ 6.42 Warrants granted 171,429 7.70 375,000 8.44 Warrants expired 40,000 10.00 25,000 9.44 Warrants cancelled, forfeited - - - - Warrants exercised 119,167 6.99 150,000 4.00 Balance, end of year 1,378,929 7.40 1,366,667 7.19 Exercisable warrants 1,295,596 $ 6.38 1,200,001 $ 7.14 Outstanding warrants as of December 31, 2021 are as follows: SCHEDULE OF OUTSTANDING WARRANTS Weighted Average Weighted Weighted Range of residual life Average Average Exercise span Outstanding Exercise Exercisable Exercise Prices (in years) Warrants Price Warrants Price 7.00 2.77 847,500 $ 7.00 847,500 $ 7.00 7.50 4.68 250,000 7.50 166,667 7.50 7.70 4.52 171,429 7.70 171,429 7.70 8.00 0.16 10,000 8.00 10,000 8.00 10.00 1.58 100,000 10.00 100,000 10.00 7.00 to 10.00 3.05 1,378,929 $ 7.40 1,295,596 $ 6.38 Warrants outstanding have the following expiry date and exercise prices as of the years ended December 31, 2021: SCHEDULE OF WARRANTS OUTSTANDING, EXPIRY DATE AND EXERCISE PRICES Exercise Expiry Date Prices 2021 2020 February 02, 2021 $ 14.00 - 15.000 August 02, 2021 2.20 - 75,000 October 10, 2021 10.00 - 25,000 February 27, 2022 8.00 10,000 10,000 May 18, 2023 10.00 50,000 50,000 October 14, 2023 10.00 50,000 50,000 October 06, 2024 7.00 847,500 891,667 September 01, 2025 7.50 83,334 83,334 June 04, 2026 7.50 83,333 83,333 July 7, 2026 7.70 171,429 - December 04, 2027 7.50 83,333 83,333 1,378,929 1,366,667 We have a stock option plan whereby the Board of Directors, may grant to directors, officers, employees, or consultants of the Company options to acquire common shares. The Board of Directors of the Company has the authority to determine the terms, limits, restrictions and conditions of the grant of options, to interpret the plan, and make all decisions relating thereto. The plan was adopted by the Company’s Board of Directors on November 17, 2014 in order to provide an inducement and serve as a long-term incentive program. The maximum number of common shares that may be reserved for issuance was set at 500,000 . The option exercise price is established by the Board of Directors and may not be lower than the market price of the common shares at the time of grant. The options may be exercised during the option period determined by the Board of Directors, which may vary, but will not exceed ten years from the date of the grant. There are 500,000 of the Company’s common shares which may be issued pursuant to the exercise of share options granted under the Plan. For options exercised during the year ended December 31, 2021, the difference between the fair value of the Common Stock issued and the respective exercise price was $ 1.5 6.6 5 Stock Options SCHEDULE OF STOCK OPTIONS GRANTED 2021 2020 Number of Weighted Number of Weighted Balance, beginning of year 1,811,550 $ 4.32 1,133,550 $ 4.00 Stock options granted - - 775,000 - Stock options expired 28,750 - - - Stock options cancelled, forfeited - - 30,250 - Stock options exercised 223,500 - 66,750 - Balance, end of year 1,559,300 4.58 1,811,550 4.32 Exercisable stock options 1,065,133 $ 4.56 999,988 $ 4.05 Outstanding stock options as of December 31, 2021, are as follows: SCHEDULE OF OUTSTANDING STOCK OPTIONS Range of Weighted Outstanding Weighted Exercisable Weighted 1.50 .01 38,017 $ 1.50 38,017 $ 1.50 1.80 .13 76,033 1.80 76,033 1.80 2.40 1.17 247,000 2.40 247,000 2.40 4.20 3.30 10,000 4.20 7,500 4.20 4.40 7.83 404,000 4.40 170,667 4.40 4.84 8.75 380,000 4.84 126,667 4.84 5.00 1.58 147,500 5.00 142,500 5.00 5.40 1.91 131,750 5.40 131,750 5.40 10.00 2.89 125,000 10.00 125,000 10.00 1.5 to 10 4.92 1,559,300 $ 4.58 1,065,134 $ 4.56 Stock options outstanding at the end of the year have the following expiry date and exercise prices: SCHEDULE OF STOCK OPTIONS, EXPIRY DATE AND EXERCISE PRICES Exercise Expiry Date Prices 31-Dec-21 31-Dec-20 August 02, 2021 $ 2.20 - 175,000 February 17, 2022 1.50 38,017 38,017 February 17, 2022 1.80 76,033 76,033 February 28, 2023 5.00 20,000 20,000 March 05, 2023 2.40 247,000 272,000 July 31, 2023 5.00 127,500 127,500 October 31, 2023 4.40 54,000 89,250 November 30, 2023 5.40 131,750 133,750 November 20, 2024 10.00 125,000 125,000 April 20, 2025 4.20 10,000 10,000 September 30, 2030 4.40 350,000 365,000 September 30, 2030 4.84 380,000 380,000 1,559,300 1,811,550 We recorded stock compensation expense relating to the vesting of stock options and warrants as follows for the years ended December 31, 2021 and 2020; SCHEDULE OF STOCK COMPENSATION EXPENSE 2021 2020 In thousands Stock compensation $ 951 $ - Stock Option vesting 1,600 709 Total $ 2,552 $ 709 |